The overall development of the pharmaceutical industry chain has been affected with the deepening of the new medical reform and the implementation of a new version of "drug administration law" and the pharmaceutical industry chain in China will experience qual. changes in product structure, drug innovation, corporate management, sales modes, valueadded services and so on.The policy-oriented results will also make the pharmaceutical distribution industry further merge and reorganize, the survival of the fittest, and accelerate the development of scale and intensification.One of its performances will cause large pharmaceutical com. group companies such as Sinopharm Holdings to accelerate the layout of the imported drug supply chain.